Restriction of Viral Glycoprotein Maturation by Cellular Protease Inhibitors

Viruses. 2024 Feb 22;16(3):332. doi: 10.3390/v16030332.

Abstract

The human genome is estimated to encode more than 500 proteases performing a wide range of important physiological functions. They digest proteins in our food, determine the activity of hormones, induce cell death and regulate blood clotting, for example. During viral infection, however, some proteases can switch sides and activate viral glycoproteins, allowing the entry of virions into new target cells and the spread of infection. To reduce unwanted effects, multiple protease inhibitors regulate the proteolytic processing of self and non-self proteins. This review summarizes our current knowledge of endogenous protease inhibitors, which are known to limit viral replication by interfering with the proteolytic activation of viral glycoproteins. We describe the underlying molecular mechanisms and highlight the diverse strategies by which protease inhibitors reduce virion infectivity. We also provide examples of how viruses evade the restriction imposed by protease inhibitors. Finally, we briefly outline how cellular protease inhibitors can be modified and exploited for therapeutic purposes. In summary, this review aims to summarize our current understanding of cellular protease inhibitors as components of our immune response to a variety of viral pathogens.

Keywords: TMPRSS2; antiviral host factors; furin; protease; protease inhibitor; serpins; viral glycoprotein.

Publication types

  • Review

MeSH terms

  • Glycoproteins / metabolism
  • Humans
  • Peptide Hydrolases / metabolism
  • Protease Inhibitors* / pharmacology
  • Proteolysis
  • Viruses* / metabolism

Substances

  • Protease Inhibitors
  • Glycoproteins
  • Peptide Hydrolases